Share Name Share Symbol Market Type Share ISIN Share Description
Port Erin LSE:PEBI London Ordinary Share IM00B6QH1J21 ORD 0.0001P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
4.00 5.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -0.21 -0.91 1
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Port Erin (PEBI) Latest News

Port Erin News

Date Time Source Headline
22/10/201913:00RNSNONAgronomics Limited Company Newsletter
31/5/201908:33ALNCFAlliance News Flash Headline
More Port Erin News
Port Erin Takeover Rumours

Port Erin (PEBI) Share Charts

1 Year Port Erin Chart

1 Year Port Erin Chart

1 Month Port Erin Chart

1 Month Port Erin Chart

Intraday Port Erin Chart

Intraday Port Erin Chart

Port Erin (PEBI) Discussions and Chat

Port Erin Forums and Chat

Date Time Title Posts
31/5/201911:39PORT ERIN BIOPHARMA - thread with charts200
18/7/201314:29Port Erin Biopharma Investments49

Add a New Thread

Port Erin (PEBI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Port Erin trades in real-time

Port Erin (PEBI) Top Chat Posts

tomboyb: My personal opinion and certainly that of other stocks is that investors by far prefer larger investment stakes in investee companies so any real upside if reflected in the share price of its own entity - Lets hope Mellon gets this one moving -
tomboyb: Should rise from here - Previous RNS showed things were not that bad and it was correct -
rivaldo: Yep, it seems like the wait continues for concrete action, whether by PEBI to reduce the discount or one of the portfolio investees to surge. Or for a press mention of the 40% discount to NAV :o)) FYI Northland have updated as follows today: "Northland Capital partners view: PEBI reported a strong gain in its Net Asset Value, up 20% YoY. Nevertheless, there is significant upside to the Company’s shares, as the Group’s market valuation still remains at a c. 50% discount to the underlying asset base. The Company's investments continue to show significant potential. Of note, Northland’s price target on one of PEBI’s portfolio holdings, namely SalvaRx, is 149p, while SalvaRx’s current share price is 30p. We also see significant upside to several other PEBI holdings."
rivaldo: Final results out today - NAV of 11.13p per share. The share price discount is described as "significant and disappointing", with "a number of options" being considered. It's decision time for DBC with PEBI's loan being due for repayment by 31st March.
rivaldo: NAV at 30/9 reported this morning at 9.96p per share, up from 9.28p: Http:// And that excludes the uplift this month from SUMM, plus any uplift from DBC's upcoming reverse into LIFE: "The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2016 was 9.96 pence per share, including un-invested cash of GBP12,921. The portfolio is valued under IFRS at bid price. Net Assets stand at GBP2.35 million including Investments of GBP2.33 million. This quarter's NAV represents an increase of 7.33% from the previous valuation of 9.28 pence per share, which included un-invested cash of GBP11,985. No additional management fee is due to Shellbay Investments Limited. The reported NAV to 30 September 2016 gained mainly due to an increase in the value of the Magna Biopharma Fund investment. The Company's three principal investments continue to show significant growth prospects for 2016 and beyond. In particular we note the positive news from Summit Therapeutics plc ("Summit") on 4 October 2016 that it had entered into an exclusive licence and collaboration agreement with Sarepta Therapeutics for Summit's utrophin modulator pipeline."
rivaldo: FYI a poster elsewhere believes PEBI own 377,654 shares in SUMM, which would now be worth £955,000. Looks like PEBI are well undervalued at the current price assuming SUMM holds its new levels. EDIT - just noticed that the SUMM holding was worth £218,291 at 30/6/16: Http:// Since SUMM's price was around 108p at that point, that implies a holding of around 200,000 shares, i.e now worth £500,000.
rivaldo: Huge deal for SUMM this morning - and their share price is up 40%. I can't see how many shares PEBI own in SUMM anywhere. The only clue is the potentially 5.3m shares in March'13 in the thread header, which would have become around 265,000 shares post 1 for 20 consolidation. So the current SUMM stake would be worth almost £500k at the now 180p.
colin12345678: For those unaware, Port Erin Biopharma’s Net Asset Value surged overnight following some spectacular developments in its portfolio companies: • Summit Therapeutics: Its NASDAQ traded stock (SMMT) shot-up by 92% initially before settling at 52.8% following a further detailed update on the hugely significant FDA clearance. Its lead drug candidate Ezutromid, worth over £600m if commercially successful, has been granted IND status, thereby paving way for a Phase II proof-of-concept trial across the U.S. From a historical perspective, and in 69% of cases, this type of FDA clearance has often led to commercial success – hence the share price surge in New York. And as the reality continues to set-in, expect further rises to follow. • Magna Biopharma Income Fund: Over the last fortnight, the value of the fund has been substantially enhanced (24.3%) following strong rises in its Dexcom, Novartis and Lannett Co. holdings. • Regent Pacific Group: Last week, RPG announced that it has entered into a binding Term Sheet with DBC (Diabetic Boot Company) in respect of a conditional subscription for up to 130,434 new DBC shares (and 65,217 Warrants) for an aggregate consideration of up to £2,999,982. This will represent approximately 33.10% of DBC! Put simply, the company is now in full control of PulseFlow Technologies. And at the last valuation in July 2015, DBC shares (privately held) were valued at £13.37 per share. Last week, the shares were valued at £23.00; an 80.5% increase in just 9 months! The company hopes to float on NASDAQ in the short to medium term. Click the ‘download report’ for the full analysis in the GECR link below. With an updated NAV of 15.8p (and rising…), hold on to your shares; the re-rate is underway.
fastbuck: Jump on low volumes this morning before further volume and some selling was attracted. Even at 8p we are still well short of the c. 11p NBV without factoring the upside in NBV when Plethora takeover is factored in at more than twice the current share price. Guess we are looking at a resultant 12p NBV then.
rivaldo: Nice rise today, presumably in anticipation of the coming cash distribution. Good summary by a poster called casper72 elsewhere dated 28th November after the distribution RNS was issued: "I read the announcement today as essentially saying: "we will buy back shares from existing shareholders and cancel them, using money from the Magna Fund". no details on price, but its fairly easy to work out the overall picture. The Magna fund value is currently about 9.6p/PEBI share, so the distribution will, after costs, deliver equivalent value to each shareholder. Lets assume that they decide to buy back 1 share for every 2 shares owned. - you get back 9.6p/share (capital gains as its a share redemption, rather than dividend, but think of it as a dividend) - total value of PEBI drops by 9.6p/share, leaving a balance sheet value of 5.8p remaining, half of this being holdings in listed shares, half unlisted - the shares in issue halve from today, so the net asset value per share doubles back up to 11.6p/share That means that the market is effectively discounting the remaining PEBI investments by 80% (difference between current offer of 10.5p share and the 9.6p distribution = 0.9p, vs. balance sheet value of 5.8p/share prior to share redemption). This seems like a material discount to me. The only complication will be the fact that PEBI will be so small at the end of this process that I don't think that it will be economically viable in the long run (would only have a market cap of £1.8m). Welcome views on the maths and other risks - I flagged that this was a good opportunity a while back - seems to be even more so now. "
Port Erin share price data is direct from the London Stock Exchange
Your Recent History
Port Erin
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191120 20:08:01